Immunic (NASDAQ:IMUX) Downgraded to Sell at StockNews.com

StockNews.com lowered shares of Immunic (NASDAQ:IMUX) from a hold rating to a sell rating in a report published on Saturday.

Separately, Brookline Capital Management reiterated a buy rating and issued a $10.00 price objective on shares of Immunic in a research report on Friday, April 5th.

Immunic Stock Performance

NASDAQ IMUX opened at $1.22 on Friday. Immunic has a one year low of $0.95 and a one year high of $3.11. The stock’s 50 day simple moving average is $1.33 and its 200 day simple moving average is $1.26.

Immunic (NASDAQ:IMUX) last announced its quarterly earnings data on Thursday, February 22nd. The company reported ($0.48) EPS for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.03. As a group, equities research analysts forecast that Immunic will post -0.99 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. RTW Investments LP boosted its position in Immunic by 0.9% in the 3rd quarter. RTW Investments LP now owns 4,335,255 shares of the company’s stock valued at $6,373,000 after buying an additional 40,796 shares during the last quarter. Gratus Capital LLC lifted its stake in shares of Immunic by 15.1% in the 4th quarter. Gratus Capital LLC now owns 1,941,454 shares of the company’s stock valued at $2,912,000 after purchasing an additional 254,999 shares during the period. Acadian Asset Management LLC lifted its stake in shares of Immunic by 26.8% in the 3rd quarter. Acadian Asset Management LLC now owns 757,250 shares of the company’s stock valued at $1,111,000 after purchasing an additional 159,973 shares during the period. Sierra Summit Advisors LLC acquired a new position in shares of Immunic in the 4th quarter valued at $487,000. Finally, Innovis Asset Management LLC lifted its stake in shares of Immunic by 46.3% in the 3rd quarter. Innovis Asset Management LLC now owns 272,457 shares of the company’s stock valued at $401,000 after purchasing an additional 86,217 shares during the period. 51.82% of the stock is currently owned by institutional investors.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.